Vitrafy Life Sciences (ASX:VFY), a cryopreservation technology company, is a core holding for Ryder Capital. In May 2026, Ryder reported positive contributions from Vitrafy as it continued to rise following an update demonstrating strong technical progress in its cryopreservation technology. In April, Ryder said Vitrafy was among core holdings driving positive performance, and in March noted it used market weakness to add to its position. Vitrafy Life Sciences operates in the Healthcare sector within the Life Sciences Tools and Services industry, and Thesis Tracker has captured 3 comments from 1 fund manager, Ryder Capital. Founded in 2017 by Brent Owens, Brian Taylor and Sean Cameron and headquartered in Melbourne, Vitrafy develops cryopreservation technology that aims to improve the freezing, storage and thawing of biological material, including cell and gene therapies, blood products, reproductive cells and agricultural genetics such as livestock semen and aquaculture, potentially improving survival rates and logistics across healthcare and agriculture markets.